Frequency and risk factors for posttransplant diabetes mellitus in Iranian renal transplant patients. 2009

S Ossareh, and S Naseem, and M A Faraji, and M Bahrami Asl, and A Yousefnejad
Department of Internal Medicine, Nephrology Ward, Hasheminejad Kidney Center, Iran University of Medical Sciences, Tehran, Iran. ossareh_s@yahoo.com

Posttransplant diabetes mellitus (PTDM) is a frequent complication of renal transplantation. This study was performed to determine the prevalence of and risk factors for PTDM among Iranian renal transplant recipients. In this cross-sectional study, 300 patients were studied in 2007. It included questionnaires with clinical data and blood samples. PTDM was defined as DM without a pretransplant history. The 184 (61.3%) male and 116 (38.7%) female patients of overall mean age of 41.2 +/- 13.5 years were 67.4 +/- 48.6 months after the procedure. PTDM was observed in 24 patients (8%). The mean interval to develop PTDM was 19.9 +/- 31.5 months. The mean age of PTDM patients was significantly higher than non-PTDM patients: 49.4 +/- 13.4 vs 40.6 +/- 13.4 years (P < .005). The mean serum high-density lipoprotein (HDL) was higher among PTDM compared with non-PTDM patients: 71.4 +/- 21 vs 58.6 +/- 14.6 (P < .005). There was a trend toward higher serum low-density lipoprotein (LDL) among PTDM patients: 109.2 +/- 29.5 vs 96.2 +/- 25.2 (P = .06). A recent admission was more frequent among PTDM patients (58.3% vs 28.7%; P < .005), as was history of hepatitis C virus (HCV) infection (6% vs 1%; P < .01). There was no significant difference in doses of immunosuppressive drugs and doses atenolol, mean body mass index, DM family history, rejection, cytomegalovirus (CMV) infection, or frequency of positive anti-HCV antibody between the 2 groups. Our study showed an 8% prevalence of PTDM. Mean age, history of recent admissions and HCV infection, as well as mean plasma HDL and LDL levels were higher among PTDM patients.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007492 Iran A country bordering the Gulf of Oman, the Persian Gulf, and the Caspian Sea, between Iraq and Pakistan. The capital is Tehran. Islamic Republic of Iran
D008075 Lipoproteins, HDL A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases. High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D008297 Male Males
D008487 Medical History Taking Acquiring information from a patient on past medical conditions and treatments. Medical History, Previous,Past Medical History, Family,Previous Medical History,Family Health History,Family History, Health,Family History, Medical,Family Medical History,History Taking, Medical,Family Health Histories,Family Medical Histories,Health Family Histories,Health Family History,Health History, Family,History, Previous Medical,Medical Family Histories,Medical Family History,Medical Histories, Previous,Medical History, Family,Previous Medical Histories
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D011795 Surveys and Questionnaires Collections of data obtained from voluntary subjects. The information usually takes the form of answers to questions, or suggestions. Community Survey,Nonrespondent,Questionnaire,Questionnaires,Respondent,Survey,Survey Method,Survey Methods,Surveys,Baseline Survey,Community Surveys,Methodology, Survey,Nonrespondents,Questionnaire Design,Randomized Response Technique,Repeated Rounds of Survey,Respondents,Survey Methodology,Baseline Surveys,Design, Questionnaire,Designs, Questionnaire,Methods, Survey,Questionnaire Designs,Questionnaires and Surveys,Randomized Response Techniques,Response Technique, Randomized,Response Techniques, Randomized,Survey, Baseline,Survey, Community,Surveys, Baseline,Surveys, Community,Techniques, Randomized Response
D012086 Reoperation A repeat operation for the same condition in the same patient due to disease progression or recurrence, or as followup to failed previous surgery. Revision, Joint,Revision, Surgical,Surgery, Repeat,Surgical Revision,Repeat Surgery,Revision Surgery,Joint Revision,Revision Surgeries,Surgery, Revision

Related Publications

S Ossareh, and S Naseem, and M A Faraji, and M Bahrami Asl, and A Yousefnejad
March 2006, Transplantation proceedings,
S Ossareh, and S Naseem, and M A Faraji, and M Bahrami Asl, and A Yousefnejad
September 2004, Transplantation proceedings,
S Ossareh, and S Naseem, and M A Faraji, and M Bahrami Asl, and A Yousefnejad
November 2005, Transplantation,
S Ossareh, and S Naseem, and M A Faraji, and M Bahrami Asl, and A Yousefnejad
May 2004, Transplantation proceedings,
S Ossareh, and S Naseem, and M A Faraji, and M Bahrami Asl, and A Yousefnejad
January 2009, Transplantation proceedings,
S Ossareh, and S Naseem, and M A Faraji, and M Bahrami Asl, and A Yousefnejad
April 2008, Transplantation proceedings,
S Ossareh, and S Naseem, and M A Faraji, and M Bahrami Asl, and A Yousefnejad
September 2009, Transplantation proceedings,
S Ossareh, and S Naseem, and M A Faraji, and M Bahrami Asl, and A Yousefnejad
February 1991, Transplantation proceedings,
S Ossareh, and S Naseem, and M A Faraji, and M Bahrami Asl, and A Yousefnejad
June 2010, Transplantation proceedings,
S Ossareh, and S Naseem, and M A Faraji, and M Bahrami Asl, and A Yousefnejad
March 2011, Transplantation proceedings,
Copied contents to your clipboard!